[Subconjunctival mitomycin C for the treatment of ocular cicatricial pemphigoid].
OBJECTIVE
We study the efficacy of treating ocular cicatricial pemphigoid (OCP) with subconjuctival mitomycin C (MMC).


METHODS
The patients were eligible for treatment under two criteria: 1. Significant complications of systemic immunosuppressant therapy. 2. Avanced stage of OCP. All patients received an injection of 0.25 ml of 0.2 mg/ml mitomycin C to both the upper and lower bulbar conjunctiva in both eyes.


RESULTS
Four patients were treated with subconjunctival mitomycin C (both eyes) and were followed for an average of 17 months (range 9-26 months). Three of four patients showed progression of the conjunctival disease and required concomitant systemic immunosuppressive therapy after subconjuctival mitomycin C.


CONCLUSIONS
No complications of subconjunctival mitomycin C treatment were noted but, contrary to what other authors had referred, its use was not effective in preventing progression of conjunctival cicatrization in our patients with OCP.
Celis Sánchez
J
J
H.G. La Mancha-Centro, Alcázar de San Juan, Ciudad Real, España. jcelis@hmct.insalud.es
López Ferrando
N
N
García Largacha
M
M
González del Valle
F
F
Ortiz de la Torre
M J
MJ
D000368:Aged; D000369:Aged, 80 and over; D001327:Autoimmune Diseases / Q000150:complications / Q000188:drug therapy*; D018450:Disease Progression; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D019085:Fluorescent Antibody Technique, Direct; D005500:Follow-Up Studies; D005901:Glaucoma / Q000150:complications; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007267:Injections; D008297:Male; D016685:Mitomycin / Q000008:administration & dosage / Q000627:therapeutic use*; D019384:Nucleic Acid Synthesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D009883:Ophthalmic Solutions / Q000008:administration & dosage / Q000627:therapeutic use*; D010390:Pemphigoid, Benign Mucous Membrane / Q000150:complications / Q000188:drug therapy*; D017211:Treatment Failure
D007166:Immunosuppressive Agents; D019384:Nucleic Acid Synthesis Inhibitors; D009883:Ophthalmic Solutions; D016685:Mitomycin